The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform
Thierry Passeron - One of the best experts on this subject based on the ideXlab platform.
-
maintenance therapy of adult vitiligo with 0 1 tacrolimus ointment a randomized double blind placebo controlled study
Journal of Investigative Dermatology, 2015Co-Authors: M Cavalie, Khaled Ezzedine, E Fontas, H Montaudie, E Castela, P Bahadoran, Alain Taieb, J P Lacour, Thierry PasseronAbstract:The risk of relapse after successful repigmentation in vitiligo is estimated to 40% within the first year. It has been shown in atopic dermatitis that continuous low-level use of topical corticosteroids and calcineurin inhibitors in previously affected skin can prevent new flares. We hypothesized that a twice-weekly application of 0.1% tacrolimus ointment might be effective for maintaining repigmentation in therapeutically repigmented lesions of vitiligo patients. After randomization, sixteen patients with 31 patches were assigned to the placebo group and 19 patients with 41 patches were assigned to the tacrolimus group. In the intention-to-treat analysis, 48.4% of lesions showed Depigmentation in the placebo group, whereas 26.8% did in the tacrolimus group (P=0.059). The intention-to-treat results did not remain significant after adjustment for within-patient clustering, odds ratio (OR) 2.55; 95% confidence interval (CI; 0.65–9.97); P=0.1765. The per-protocol analysis (n=56) showed that 40% of lesions had some Depigmentation in the placebo group, whereas only 9.7% did in the tacrolimus group (P=0.0075). The per-protocol results remained significant after adjustment for within-patient clustering: OR 6.22; 95% CI (1.48–26.12); P=0.0299. Our study shows that twice-weekly application of 0.1% tacrolimus ointment is effective in preventing the Depigmentation of vitiligo patches that have been previously successfully repigmented.
-
laser assisted Depigmentation for resistant vitiligo a retrospective case series with long term follow up
Journal of The European Academy of Dermatology and Venereology, 2014Co-Authors: F Boukari, P Bahadoran, J P Lacour, J P Ortonne, Thierry PasseronAbstract:Abstract Background Blanching creams are used to depigment and to achieve uniform skin tone in widespread vitiligo.Length of the treatment and side-effects strongly limit their use in common practice.Objectives To assess the long-term efficacy and tolerance of Q-Switched (QS) lasers for depigmenting theremaining unaffected skin in vitiligo.Methods Retrospective study of vitiligo patients treated with QS lasers in the Department of Dermatology of theUniversity Hospital of Nice, France, from 2002 to 2011. Localizations and the percentage of body surface area oftreated lesions, the total number of sessions and the possible relapses and side-effects, were analysed. Globalsatisfaction of the patients was evaluated on a visual analogical scale.Results Sixteen areas of normally pigmented skin were treated in six patients. The median number of sessions toachieve a complete Depigmentation was 2 (1–6). The mean duration of follow-up was 36 months (19–120). One thirdof the patients had no relapse. A complete repigmentation was observed after 21 months in one patient; a 50%repigmentation was noted in one patient, 7 months after the end of the treatment. Two patients showed a minimalrepigmentation (<25%), 18 months and 9 years after the first laser treatments. The repigmentations were effectivelytreated with a maintenance session. The mean total number of sessions performed during this period was 3 (1–20).Side-effects were limited to transient purpura and crusts. The satisfaction of the patients was excellent (mean 9⁄10).Conclusions QS lasers appear as an efficient and safe modality for depigmenting normal skin in vitiligo.Received: 04 July 2012; Accepted: 05 October 2012
-
topical tacrolimus and the 308 nm excimer laser a synergistic combination for the treatment of vitiligo
Archives of Dermatology, 2004Co-Authors: Thierry Passeron, E Fontas, J P Lacour, Nima Ostovari, Wassim Zakaria, Jeanclaude Larrouy, Jeanpaul OrtonneAbstract:Results: Forty-three lesions were treated (23 in group A and 20 in group B). All patients completed the study. Repigmentation was observed in all group A lesions (100%) and in 17 (85%) of the 20 group B lesions. Repigmentation was not observed in the untreated lesions (control group). A repigmentation rate of 75% or more was obtained in 16 (70%) of the 23 group A lesions and in4(20%)ofthe20groupBlesions.InUV-sensitiveareas (the face, neck, trunk, and limbs, with the exception of bonyprominencesandextremities),10(77%)of13group A lesions had a repigmentation rate of 75% or more vs 4 (57%) of 7 group B lesions. In classically UV-resistant areas, 6 (60%) of 10 group A lesions had a repigmentation rate of 75% or more vs 0 of the 13 group B lesions. The mean number of sessions necessary for an improvementofrepigmentationwas10ingroupAand12ingroup B. Adverse effects have been limited, and tolerance was excellent.
Shigeaki Ohno - One of the best experts on this subject based on the ideXlab platform.
-
Trabecular meshwork Depigmentation in Vogt–Koyanagi–Harada disease
Japanese Journal of Ophthalmology, 2013Co-Authors: Kazuomi Mizuuchi, Nobuyoshi Kitaichi, Kenichi Namba, Yukihiro Horie, Susumu Ishida, Shigeaki OhnoAbstract:Purpose Since some patients develop Depigmentation of the trabecular meshwork in the course of Vogt–Koyanagi–Harada (VKH) disease, we examined the incidence of trabecular Depigmentation and its correlation with other ocular findings and systemic symptoms. Methods We retrospectively reviewed the clinical charts of 53 Japanese patients diagnosed with VKH disease. The scores of trabecular and limbal pigmentation of all patients were recorded. We then examined the correlation between trabecular pigmentation and the presence of sunset glow fundus or skin lesions. Results Trabecular pigmentation was significantly lower in the patients with sunset glow fundus than in those without it ( P = 0.022), whereas limbal pigmentation showed no significance. However, there were no significant differences in trabecular and limbal pigmentation between the patients with and those without skin lesions. Furthermore, there was no correlation between trabecular and limbal pigmentation. Conclusions Depigmentation of the trabecular meshwork develops in some patients in the course of VKH disease. This Depigmentation is significantly correlated with sunset glow fundus, but not with limbal Depigmentation or skin lesions.
-
Trabecular meshwork Depigmentation in Vogt-Koyanagi-Harada disease.
Japanese journal of ophthalmology, 2013Co-Authors: Kazuomi Mizuuchi, Nobuyoshi Kitaichi, Kenichi Namba, Yukihiro Horie, Susumu Ishida, Shigeaki OhnoAbstract:Since some patients develop Depigmentation of the trabecular meshwork in the course of Vogt–Koyanagi–Harada (VKH) disease, we examined the incidence of trabecular Depigmentation and its correlation with other ocular findings and systemic symptoms. We retrospectively reviewed the clinical charts of 53 Japanese patients diagnosed with VKH disease. The scores of trabecular and limbal pigmentation of all patients were recorded. We then examined the correlation between trabecular pigmentation and the presence of sunset glow fundus or skin lesions. Trabecular pigmentation was significantly lower in the patients with sunset glow fundus than in those without it (P = 0.022), whereas limbal pigmentation showed no significance. However, there were no significant differences in trabecular and limbal pigmentation between the patients with and those without skin lesions. Furthermore, there was no correlation between trabecular and limbal pigmentation. Depigmentation of the trabecular meshwork develops in some patients in the course of VKH disease. This Depigmentation is significantly correlated with sunset glow fundus, but not with limbal Depigmentation or skin lesions.
Paradi Mirmirani - One of the best experts on this subject based on the ideXlab platform.
-
hair Depigmentation during chemotherapy with a class iii v receptor tyrosine kinase inhibitor
Archives of Dermatology, 2006Co-Authors: Shannon B Routhouska, Anita C Gilliam, Paradi MirmiraniAbstract:Background Hair pigmentation is regulated by several factors including the interaction of the ligand stem cell factor (SCF) with its class III receptor tyrosine kinase, c-kit. An interruption of SCF/c-kit signal transduction results in hair Depigmentation. Observations A 69-year-old white woman developed hair Depigmentation and fine-textured hair while being treated with the phase I chemotherapeutic agent GW786034, a class III/V receptor tyrosine kinase inhibitor. Discontinuation of therapy resulted in a reversal of these hair changes. Conclusions Treatment with oral GW786034 resulted in reversible hair Depigmentation and change in hair growth rate and texture, which were most likely due to an incomplete inhibition of SCF/c-kit signaling, although the exact mechanism is unknown. It would be intriguing to investigate topical tyrosine kinase inhibitors as a treatment for unwanted body hair.
J P Lacour - One of the best experts on this subject based on the ideXlab platform.
-
maintenance therapy of adult vitiligo with 0 1 tacrolimus ointment a randomized double blind placebo controlled study
Journal of Investigative Dermatology, 2015Co-Authors: M Cavalie, Khaled Ezzedine, E Fontas, H Montaudie, E Castela, P Bahadoran, Alain Taieb, J P Lacour, Thierry PasseronAbstract:The risk of relapse after successful repigmentation in vitiligo is estimated to 40% within the first year. It has been shown in atopic dermatitis that continuous low-level use of topical corticosteroids and calcineurin inhibitors in previously affected skin can prevent new flares. We hypothesized that a twice-weekly application of 0.1% tacrolimus ointment might be effective for maintaining repigmentation in therapeutically repigmented lesions of vitiligo patients. After randomization, sixteen patients with 31 patches were assigned to the placebo group and 19 patients with 41 patches were assigned to the tacrolimus group. In the intention-to-treat analysis, 48.4% of lesions showed Depigmentation in the placebo group, whereas 26.8% did in the tacrolimus group (P=0.059). The intention-to-treat results did not remain significant after adjustment for within-patient clustering, odds ratio (OR) 2.55; 95% confidence interval (CI; 0.65–9.97); P=0.1765. The per-protocol analysis (n=56) showed that 40% of lesions had some Depigmentation in the placebo group, whereas only 9.7% did in the tacrolimus group (P=0.0075). The per-protocol results remained significant after adjustment for within-patient clustering: OR 6.22; 95% CI (1.48–26.12); P=0.0299. Our study shows that twice-weekly application of 0.1% tacrolimus ointment is effective in preventing the Depigmentation of vitiligo patches that have been previously successfully repigmented.
-
laser assisted Depigmentation for resistant vitiligo a retrospective case series with long term follow up
Journal of The European Academy of Dermatology and Venereology, 2014Co-Authors: F Boukari, P Bahadoran, J P Lacour, J P Ortonne, Thierry PasseronAbstract:Abstract Background Blanching creams are used to depigment and to achieve uniform skin tone in widespread vitiligo.Length of the treatment and side-effects strongly limit their use in common practice.Objectives To assess the long-term efficacy and tolerance of Q-Switched (QS) lasers for depigmenting theremaining unaffected skin in vitiligo.Methods Retrospective study of vitiligo patients treated with QS lasers in the Department of Dermatology of theUniversity Hospital of Nice, France, from 2002 to 2011. Localizations and the percentage of body surface area oftreated lesions, the total number of sessions and the possible relapses and side-effects, were analysed. Globalsatisfaction of the patients was evaluated on a visual analogical scale.Results Sixteen areas of normally pigmented skin were treated in six patients. The median number of sessions toachieve a complete Depigmentation was 2 (1–6). The mean duration of follow-up was 36 months (19–120). One thirdof the patients had no relapse. A complete repigmentation was observed after 21 months in one patient; a 50%repigmentation was noted in one patient, 7 months after the end of the treatment. Two patients showed a minimalrepigmentation (<25%), 18 months and 9 years after the first laser treatments. The repigmentations were effectivelytreated with a maintenance session. The mean total number of sessions performed during this period was 3 (1–20).Side-effects were limited to transient purpura and crusts. The satisfaction of the patients was excellent (mean 9⁄10).Conclusions QS lasers appear as an efficient and safe modality for depigmenting normal skin in vitiligo.Received: 04 July 2012; Accepted: 05 October 2012
-
topical tacrolimus and the 308 nm excimer laser a synergistic combination for the treatment of vitiligo
Archives of Dermatology, 2004Co-Authors: Thierry Passeron, E Fontas, J P Lacour, Nima Ostovari, Wassim Zakaria, Jeanclaude Larrouy, Jeanpaul OrtonneAbstract:Results: Forty-three lesions were treated (23 in group A and 20 in group B). All patients completed the study. Repigmentation was observed in all group A lesions (100%) and in 17 (85%) of the 20 group B lesions. Repigmentation was not observed in the untreated lesions (control group). A repigmentation rate of 75% or more was obtained in 16 (70%) of the 23 group A lesions and in4(20%)ofthe20groupBlesions.InUV-sensitiveareas (the face, neck, trunk, and limbs, with the exception of bonyprominencesandextremities),10(77%)of13group A lesions had a repigmentation rate of 75% or more vs 4 (57%) of 7 group B lesions. In classically UV-resistant areas, 6 (60%) of 10 group A lesions had a repigmentation rate of 75% or more vs 0 of the 13 group B lesions. The mean number of sessions necessary for an improvementofrepigmentationwas10ingroupAand12ingroup B. Adverse effects have been limited, and tolerance was excellent.
Henry H Chan - One of the best experts on this subject based on the ideXlab platform.
-
a case series of facial Depigmentation associated with low fluence q switched 1 064 nm nd yag laser for skin rejuvenation and melasma
Lasers in Surgery and Medicine, 2010Co-Authors: Nicola P Y Chan, Samantha Y N Shek, Chi K Yeung, Henry H ChanAbstract:Background and Objective In recent years, “laser toning” using low fluence, large spot size, multiple passed Q-switched 1,064 nm Nd:YAG laser has gained much popularity in Asian countries for non-ablative skin rejuvenation and the treatment of melasma. This case series highlights one of the complications associated with laser toning, which is facial Depigmentation. Materials and Methods Fourteen patients with laser toning-associated facial Depigmentation were assessed with cross-polarized and ultraviolet (UV) photographic images. The laser toning regimens received by these patients, as well as the treatment given for Depigmentation, were analyzed retrospectively. Results All 14 patients were Chinese females, 9 of whom received laser toning for non-ablative skin rejuvenation and the other 5 for melasma. The treatment regimens received by these patients were highly variable. The total number of treatments received ranged from 6 to 50 (mean 22.07). In all cases, UV photographic images demonstrated facial mottled Depigmentation. Laser toning failed to significantly improve melasma in all five patients. Five patients received targeted narrowband UVB for Depigmentation with good clinical results. Conclusions Laser toning with low fluence Q-switched 1,064 nm Nd:YAG laser for skin rejuvenation and melasma can be associated with mottled Depigmentation. With laser toning being frequently performed, this complication may become more commonly encountered in clinical practice. The Depigmentation can appear after only a few treatment sessions, and can cause much disfigurement, especially in cases with background melasma. Further studies on laser toning are needed with the view to optimizing efficacy and minimizing side-effects. Lasers Surg. Med. 42:712–719, 2010 © 2010 Wiley-Liss, Inc.